HGSI NVS: The monthly Albuferon data are ho-hum at best, IMO. In no way do these results suggest that Albuferon would garner more commercial success if dosed monthly rather than biweekly, which is the dosing schedule in the pending BLA/MAA. All told, I continue to think that Albuferon will be a commercial bust.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.